BiotechTube

Tideglusib

Phase 2/3Recruiting
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Congenital Myotonic Dystrophy

Conditions

Congenital Myotonic Dystrophy

Trial Timeline

Aug 23, 2021 → Dec 31, 2026

NCT ID
NCT05004129

About Tideglusib

Tideglusib is a phase 2/3 stage product being developed by AMO Pharma for Congenital Myotonic Dystrophy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05004129. Target conditions include Congenital Myotonic Dystrophy.

What happened to similar drugs?

4 of 20 similar drugs in Congenital Myotonic Dystrophy were approved

Approved (4) Terminated (0) Active (16)
🔄turoctocog alfa + turoctocog alfaNovo NordiskPhase 3
🔄turoctocog alfa pegolNovo NordiskPhase 3
🔄nonacog beta pegolNovo NordiskPhase 3
🔄vatreptacog alfa (activated) + eptacog alfa (activated)Novo NordiskPhase 3
🔄nonacog beta pegolNovo NordiskPhase 3
🔄turoctocog alfa + turoctocog alfaNovo NordiskPhase 3
✅turoctocog alfaNovo NordiskApproved

Hype Score Breakdown

Clinical
15
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT07119775Pre-clinicalActive
NCT05004129Phase 2/3Recruiting
NCT02858908Phase 2Completed

Competing Products

20 competing products in Congenital Myotonic Dystrophy

See all competitors
ProductCompanyStageHype Score
TideglusibAMO PharmaPre-clinical
20
Tideglusib + PlaceboAMO PharmaPhase 2/3
28
EDIT-101Editas MedicinePhase 1/2
18
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
17
SPR001Spruce BiosciencesPhase 2
25
SPR001Spruce BiosciencesPhase 2
25
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
17
TildacerfontSpruce BiosciencesPhase 2
17
KW-3357Kyowa KirinPhase 1
29
Pasireotide 0.6Mg Solution for Injection + Saline SolutionNovartisPhase 2
27
Sandostatine LPNovartisPhase 2
35
mycophenolate mofetilRochePhase 1
29
turoctocog alfa + turoctocog alfaNovo NordiskPhase 3
40
catridecacog + recombinant factor XIIINovo NordiskPhase 1
29
activated recombinant human factor VIINovo NordiskPhase 2
35
turoctocog alfa pegolNovo NordiskPhase 3
40
recombinant factor XIIINovo NordiskPre-clinical
26
activated recombinant human factor VII, long acting + activated recombinant human factor VII, long actingNovo NordiskPhase 1
29
Advate® + turoctocog alfaNovo NordiskPhase 1
29
nonacog beta pegolNovo NordiskPhase 3
40